Chong Kun Dang Holdings (KOSE:A001630) - Share price, News & Analysis

Q: What is the Fair Price of A001630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A001630 (₩53900) is trading above our estimate of [[fair value]] (₩36997.89)

A001630 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	1/6
Financial Health	3/6
Dividends	1/6

A001630 Stock Overview

Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally.

Risk Analysis

Earnings have declined by 3.6% per year over past 5 years

Dividend of 2.6% is not well covered by earnings or cash flows

Profit margins (0.3%) are lower than last year (6.7%)

Chong Kun Dang Holdings Competitors

Whan In PharmLtd

KOSE:A016580

₩260.3b

Kwang Dong Pharmaceutical

KOSE:A009290

₩246.9b

Daewon Pharmaceutical

KOSE:A003220

₩321.3b

JETEMA

KOSDAQ:A216080

₩260.8b

Price History & Performance

Summary of all time highs, changes and price drops for Chong Kun Dang Holdings
Historical stock prices
Current Share Price	₩53,900.00
52 Week High	₩91,900.00
52 Week Low	₩53,800.00
Beta	0.48
1 Month Change	-9.87%
3 Month Change	-4.43%
1 Year Change	-39.17%
3 Year Change	-41.98%
5 Year Change	-22.89%
Change since IPO	75.68%

Recent News & Updates

Apr 28

Here's Why Chong Kun Dang Holdings (KRX:001630) Has A Meaningful Debt Burden

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Apr 08

Could Chong Kun Dang Holdings Corp. (KRX:001630) Have The Makings Of Another Dividend Aristocrat?

Dividend paying stocks like Chong Kun Dang Holdings Corp. ( KRX:001630 ) tend to be popular with investors, and for...

Shareholder Returns

	A001630	KR Pharmaceuticals	KR Market
7D	-3.6%	-8.8%	-4.1%
1Y	-39.2%	-38.9%	-27.4%

Return vs Industry: A001630 matched the KR Pharmaceuticals industry which returned -38.9% over the past year.

Return vs Market: A001630 underperformed the KR Market which returned -27.4% over the past year.

Price Volatility

Is A001630's price volatile compared to industry and market?
A001630 volatility
A001630 Average Weekly Movement	2.3%
Pharmaceuticals Industry Average Movement	4.7%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	10.5%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A001630 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: A001630's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1941	40	Tae Young Kim	https://www.ckd-holdings.com/company/summary.do

Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Chong Kun Dang Holdings Fundamentals Summary

How do Chong Kun Dang Holdings's earnings and revenue compare to its market cap?
A001630 fundamental statistics
Market Cap	₩263.91b
Earnings (TTM)	₩2.30b
Revenue (TTM)	₩906.92b

115.0x

P/E Ratio

0.3x

P/S Ratio

Is A001630 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A001630 income statement (TTM)
Revenue	₩906.92b
Cost of Revenue	₩495.07b
Gross Profit	₩411.85b
Other Expenses	₩409.55b
Earnings	₩2.30b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	468.82
Gross Margin	45.41%
Net Profit Margin	0.25%
Debt/Equity Ratio	48.0%

How did A001630 perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

302%

Payout Ratio

We’ve recently updated our valuation analysis.

Valuation

Is A001630 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A001630?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A001630. This is calculated by dividing A001630's market cap by their current preferred multiple.
What is A001630's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	₩263.91b

A001630 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	22x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A001630's PE Ratio compare to its peers?

A001630 PE Ratio vs Peers

The above table shows the PE ratio for A001630 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	22.3x
A016580 Whan In PharmLtd	11x	7.2%	₩260.3b
A009290 Kwang Dong Pharmaceutical	9.5x	n/a	₩246.9b
A003220 Daewon Pharmaceutical	10.7x	6.3%	₩321.3b
A216080 JETEMA	12.4x	n/a	₩260.8b
A001630 Chong Kun Dang Holdings	115x	n/a	₩263.9b

Price-To-Earnings vs Peers: A001630 is expensive based on its Price-To-Earnings Ratio (115x) compared to the peer average (22.3x).

Price to Earnings Ratio vs Industry

How does A001630's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

Price-To-Earnings vs Industry: A001630 is expensive based on its Price-To-Earnings Ratio (115x) compared to the KR Pharmaceuticals industry average (20.1x)

Price to Earnings Ratio vs Fair Ratio

What is A001630's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A001630 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	115x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A001630's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of A001630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A001630 (₩53900) is trading above our estimate of fair value (₩36997.89)

Significantly Below Fair Value: A001630 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Chong Kun Dang Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

40.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chong Kun Dang Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of A001630’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Chong Kun Dang Holdings performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-3.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A001630 has high quality earnings.

Growing Profit Margin: A001630's current net profit margins (0.3%) are lower than last year (6.7%).

Past Earnings Growth Analysis

Earnings Trend: A001630's earnings have declined by 3.6% per year over the past 5 years.

Accelerating Growth: A001630's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A001630 had negative earnings growth (-96.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4%).

Return on Equity

High ROE: A001630's Return on Equity (-0.7%) is considered low.

Discover strong past performing companies

Financial Health

How is Chong Kun Dang Holdings's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A001630's short term assets (₩426.4B) exceed its short term liabilities (₩354.6B).

Long Term Liabilities: A001630's short term assets (₩426.4B) exceed its long term liabilities (₩206.3B).

Debt to Equity History and Analysis

Debt Level: A001630's net debt to equity ratio (31.5%) is considered satisfactory.

Reducing Debt: A001630's debt to equity ratio has increased from 12.2% to 48% over the past 5 years.

Debt Coverage: A001630's debt is not well covered by operating cash flow (11.6%).

Interest Coverage: Insufficient data to determine if A001630's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

Dividend

What is Chong Kun Dang Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

2.60%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A001630's dividend (2.6%) is higher than the bottom 25% of dividend payers in the KR market (1.02%).

High Dividend: A001630's dividend (2.6%) is low compared to the top 25% of dividend payers in the KR market (3.26%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, A001630 has been paying a dividend for less than 10 years.

Growing Dividend: A001630's dividend payments have increased, but the company has only paid a dividend for 3 years.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (301.9%), A001630's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: A001630 is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Tae Young Kim

no data

Tenure

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 9 shareholders own 51.74% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
47.96%	Jang-Han Lee	2,348,106	₩126.6b	0.04%	no data
1.88%	The Vanguard Group, Inc.	91,919	₩5.0b	0%	no data
1.02%	Dimensional Fund Advisors LP	49,966	₩2.7b	0.35%	no data
0.6%	Mackenzie Financial Corporation	29,316	₩1.6b	0%	no data
0.12%	AXA Investment Managers S.A.	5,805	₩312.9m	0%	no data
0.11%	Charles Schwab Investment Management, Inc.	5,564	₩299.9m	0%	no data
0.038%	Thrivent Investment Management, Inc.	1,844	₩99.4m	0%	no data
0.015%	Goldman Sachs Asset Management, L.P.	738	₩39.8m	0%	no data
0.0032%	American Century Investment Management Inc	154	₩8.3m	-51.42%	no data

Data	Last Updated (UTC time)
Company Analysis	2022/09/24 00:00
End of Day Share Price	2022/09/23 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31